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To induce a deployable level of efﬁcacy, a successful 
malaria vaccine would likely beneﬁt from both potent 
cellular and humoral immunity. These requirements are 
met by a heterologous prime-boost immunization strat-
egy employing a chimpanzee adenovirus vector followed 
by modiﬁed vaccinia Ankara (MVA), both encoding the 
pre-erythrocytic malaria antigen ME-thrombospondin-
related adhesive protein (TRAP), with high immunoge-
nicity and signiﬁcant efﬁcacy in UK adults. We undertook 
two phase 1b open-label studies in adults in Kenya and 
The Gambia in areas of similar seasonal malaria transmis-
sion dynamics and have previously reported safety and 
basic immunogenicity data. We now report ﬂow cytom-
etry and additional interferon (IFN)-γ enzyme-linked 
immunospot (ELISPOT) data characterizing pre-existing 
and induced cellular immunity as well as anti-TRAP IgG 
responses. T-cell responses induced by vaccination aver-
aged 1,254 spot-forming cells (SFC) per million periph-
eral blood mononuclear cells (PBMC) across both trials 
and ﬂow cytometry revealed cytokine production from 
both CD4+ and CD8+ T cells with the frequency of CD8+ 
IFN-γ-secreting monofunctional T cells (previously shown 
to associate with vaccine  efﬁcacy) particularly high in 
Kenyan adults. Immunization with ChAd63 and MVA 
ME-TRAP induced strong cellular and humoral immune 
responses in adults living in two malaria-endemic regions 
of Africa. This prime-boost approach targeting the pre-
erythrocytic stage of the malaria life-cycle is now being 
assessed for efﬁcacy in a target population.
Received 26 April 2014; accepted 8 June 2014; advance online  
publication 29 July 2014. doi:10.1038/mt.2014.109
INTRODUCTION
Approximately 1.2 billion people worldwide are at high risk of 
malaria and there were an estimated 207 million cases of malaria 
in 2012, with 90% occurring in sub-Saharan Africa and 57% of 
the African population living in areas of moderate to high trans-
mission intensity.1,2 Malaria caused by Plasmodium falciparum 
remains one of the leading causes of death in children under 
5 years of age in sub-Saharan Africa, despite the deployment of 
multiple control strategies such as the distribution of insecticide-
treated nets, indoor residual spraying, and intermittent preventive 
treatment.3 An effective infant vaccine for malaria could substan-
tially reduce the burden of disease and levels of malaria mortality 
and morbidity. The 2013 Malaria Vaccine Funders Group malaria 
vaccine roadmap has a landmark goal of producing a first-gen-
eration malaria vaccine by 2015 with greater than 50% efficacy 
against severe disease with greater than 1 year’s duration.4 The 
current leading malaria vaccine candidate, RTS,S, is undergo-
ing phase 3 trials across Africa in some 16,000 infants, however 
despite inducing sterile efficacy in a high proportion of malaria-
naive adult volunteers,5 observed efficacy of vaccination with 
RTS,S/AS02 was only 30% in the target age group of 6–12-week-
old infants and 50% among 5–17 month olds in malaria-endemic 
regions.6 Immune responses induced by vaccination with RTS,S 
include both humoral- and T-cell responses, however the cellu-
lar immune response is exclusively CD4+ T-cell-mediated and 
relatively  modest.7,8 Studies of protective efficacy in rodent models 
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repeatedly show that high frequencies of CD8+ T cells are essen-
tial for sterile protection9; this and evidence from animal mod-
els10–12 and studies in humans of vaccination with attenuated 
sporozoites,13 suggest that a successful malaria vaccine will ben-
efit from both a humoral and cellular component. Therefore, it is 
highly likely that an additional component capable of generating 
high frequencies of CD8+ T cells will be beneficial to complement 
the protection afforded by RTS,S or any other antibody-inducing 
malaria vaccine.14
The Jenner Institute at Oxford University has been developing 
a program of viral vectored vaccines against infectious diseases 
including malaria for the past 14 years, the most promising of 
which utilizes the full length pre-erythrocytic antigen thrombos-
pondin-related adhesive protein (TRAP) fused to a multi-epitope 
(ME) string of known T-cell epitopes.15 In previous studies with 
the ME-TRAP antigen, initial results in malaria naive volunteers 
in the United Kingdom were promising with strategies such as 
priming with a fowlpox vector (FP9) and boosting with modified 
vaccinia Ankara (MVA),16 however results of subsequent immu-
nogenicity studies in target populations in Africa were disap-
pointing with immune responses detected at levels only a small 
fraction of those in naive adult subjects.17,18 In consecutive studies, 
responses in adult UK volunteers averaged 475 spot-forming cells 
(SFC) per million peripheral blood mononuclear cells (PBMC) 
compared to 389 SFC/106 PBMC in coastal Kenya, which fell to 
105 SFC/106 PBMC in Kenyan children aged 1–6 years demon-
strating the difficulty in translating immunogenicity outcomes 
between populations.16,19,20
More recently, very potent cellular immune responses to 
ME-TRAP have been elicited by replacing the poxvirus priming 
vector with a chimpanzee adenovirus (ChAd63).21–23 The advan-
tages of using chimpanzee adenoviruses rather than human 
serotypes include an excellent safety profile and enhanced immu-
nogenicity as a consequence of lower levels of pre-existing neu-
tralizing antibodies against the vector in the target populations 
for vaccination. A phase 1 safety and dose-escalation study 
Figure 1  Ex vivo IFN-γ ELISPOT responses pre- and postvaccination to ChAd63 and modiﬁed vaccinia Ankara (MVA) ME-TRAP-vectored 
 vaccines in Gambian, Kenyan, and UK volunteers from a controlled human malaria infection trial vaccinated with the same construct. All volun-
teers received one dose of ChAd63 ME-TRAP followed by one dose of MVA ME-TRAP 8 weeks later. (a) Prevaccination responses to TRAP. (b) Responses 
to TRAP at 14 days postprime with ChAd63, ****P ≤ 0.0001, P = 0.03. (c) Responses to TRAP at day 63 (7 days postboost with MVA), ***P = 0.0002, 
**P = 0.003, *P = 0.04. (d) Responses to TRAP at day 300 postprime with ChAd63, ****P ≤ 0.0001, *P = 0.03. (e–g) Responses to the ME string in 
Gambian, Kenyan, and UK volunteers, *P < 0.05, **P < 0.01, ***P < 0.001. ELISPOT responses to peptides from different strains were compared a using 
two-tailed Wilcoxon-matched pairs analysis. Increases in ELISPOT responses to ME were compared to responses at day 0 using Kruskall-Wallis with 
Dunn’s multiple comparison posttest. Lines represent medians. ELISPOT, enzyme-linked immunospot; TRAP, thrombospondin-related adhesive protein.
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demonstrated a good safety profile for ChAd63 ME-TRAP, and 
when combined with MVA ME-TRAP in a heterologous prime-
boost approach induced T-cell frequencies of more than 2,000 
SFC per million PBMC in adult UK volunteers.21
Between May 2010 and May 2011, we undertook two phase 1b 
trials of heterologous prime-boost with ChAd63-MVA ME-TRAP 
to study the effect of vaccine dose and route of administration 
on safety and immunogenicity profiles in Kenyan and Gambian 
adults. The trials were carried out in areas of similar malaria trans-
mission characteristics. Volunteers received a priming vaccination 
with the simian adenovirus ChAd63, followed by a boosting dose 
of MVA 8 weeks later, with both vectors encoding ME-TRAP anti-
gen. Previous immunogenicity and efficacy studies with this regi-
men in UK volunteers showed a good safety profile, very potent 
T-cell induction, and protection against experimental malaria in 
a controlled human malaria infection (CHMI) model.21 Efficacy 
was observed both through sterilizing immunity in 21% of recipi-
ents and a significant delay to patent parasitemia as determined by 
blood film microscopy in a further 34% of vaccinees, thus giving 
some degree of efficacy in more than half of vaccinees.24
Primary outcomes for these two phase 1b studies in malaria-
endemic areas and the UK CHMI study reported previously24,25 
demonstrated an excellent safety profile combined with induction 
of potent cellular immune responses assessed by ex vivo IFN-γ 
ELISPOT. Here, we present additional analyses of cellular immu-
nogenicity across all three groups (i.e., Kenyan, Gambian, and UK 
adults) using both flow cytometry and IFN-γ ELISPOT on freshly 
isolated PBMC, as well as determination of humoral immunity 
by IgG enzyme-linked immunosorbent assay (ELISA) titer. Using 
this combination of simian adenovirus priming and poxvirus 
boosting vaccination, we demonstrate translation of the potent 
immunogenicity of vectored vaccines from malaria naive to semi-
immune populations in Kenya and The Gambia.
RESULTS
High-level immunogenicity following prime-boost 
vaccination in semi-immune adults
Prevaccination responses to both strains of the TRAP antigen 
were compared using the ex vivo IFN-γ ELISPOT assay, between 
the African trial sites and a previous UK trial with the same vec-
tors to assess pre-existing immunity to the candidate vaccine anti-
gen.24 No significant differences to either the T9/96 or 3D7 strain 
of P. falciparum (Figure 1a and Table 1) were observed between 
volunteers in the malaria-endemic regions where the field trials 
were performed and malaria-naive volunteers enrolled in a phase 
2a controlled human malaria infection CHMI study of the same 
viral vectors in the United Kingdom.24
Priming vaccination with ChAd63 ME-TRAP induced mod-
est T-cell responses after 14 days to peptides of the T9/96 strain 
of the TRAP antigen and these were slightly higher in Gambian 
than Kenyan vaccinees (group geometric means, 95% confidence 
intervals (CI) and P values for increases in ELISPOT response are 
shown in Table 1). Responses to the heterologous 3D7 strain of 
TRAP were significantly lower than those to the T9/96 vaccine 
strain in both trials at this time point (Figure 1b). Responses did 
not differ significantly to those in malaria naive adults.
Boosting with MVA ME-TRAP significantly increased the 
magnitude of IFN-γ ELISPOT responses to T9/96 in both trials, 
peaking at 1015 SFC/106 PBMC, (CI: 765–1,347) in the Gambian 
trial (P < 0.0001 compared to D14 responses) and 467 SFC/106 
PBMC, (CI: 247–885; P = 0.0064) in Kenya. Peak responses in 
Gambians were higher than those in Kenyans (P = 0.04). When 
responses in vaccinees receiving the highest dose of ChAd63 
(5 × 1010 viral particles (vp)) were combined across both trials, 
immunity to the T9/96 strain peaked at 1254 SFC/106 PBMC (CI: 
912–1,724). Immunity to the 3D7 strain of TRAP also significantly 
increased after MVA vaccination to 901 SFC/106 PBMC in the 
Gambian (CI: 665–1,123; P < 0.0001) and 422 SFC/106 PBMC in 
Kenyan recipients (CI: 214–833; P = 0.0005; Figure 1c). For both 
strains, peak responses were lower in semi-immune adults than 
naive adults at the same time point, notably in Kenyans where the 
response was significantly lower (P < 0.01, Kruskall-Wallis test 
with Dunn’s test for multiple comparisons, Table 1)
Immunogenicity was reassessed 8 months after MVA vaccina-
tion and plateaued at a level significantly higher than measured 
at baseline in Gambian participants. Responses in Kenyan volun-
teers at the same time point were only slightly higher than those 
detected prior to ChAd63 vaccination (Figure 1d).
Responses to the ME string of the ME-TRAP vaccine construct 
were substantially lower than to the TRAP antigen component. 
Table 1 Geometric mean IFN-γ ELISPOT responses by trial site, time 
point, and strain of Plasmodium falciparum used for TRAP peptide pool
Trial
Time 
point
TRAP 
strain
Geomean 
SFC 95% CI P value
Gambia + Kenya 0 T9/96 50 38–65 0.5
UK 0 T9/96 46 33–65
Gambia + Kenya 0 3D7 48 36–62 0.25
UK 0 3D7 61 36–103
The Gambia 14 T9/96 172 111–265 <0.0001
Kenya 14 T9/96 130 63–269 0.06
UK 14 T9/96 242 122–480 nt
The Gambia 14 3D7 137 29–211 <0.0001
Kenya 14 3D7 91 42–197 0.2
UK 14 3D7 194 94–402 nt
The Gambia 63 T9/96 1015 765–1,347 <0.0001
Kenya 63 T9/96 467 247–885 0.006
UK 63 T9/96 1524 728–3,194 nt
The Gambia 63 3D7 901 665–1,123 <0.0001
Kenya 63 3D7 422 214–833 0.0005
UK 63 3D7 1009 473–2,150 nt
The Gambia 308 T9/96 112 79–159 0.0004
Kenya 300 T9/96 92 48–175 0.2
The Gambia 308 3D7 82 58–116 0.007
Kenya 300 3D7 82 38–177 0.2
P values are for Wilcoxon-matched-pairs signed rank test (two-tailed), 
 comparing responses to postvaccination to those at time point 0. Responses 
in UK vaccinees at the ﬁnal time point were not comparable as CHMI was 
 performed at D77.
CHMI, controlled human malaria infection; CI, conﬁdence interval; 
ELISPOT, enzyme-linked immunospot; IFN,  interferon; nt, not tested; TRAP, 
 thrombospondin-related adhesive protein.
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In The Gambia, responses peaked at 94 SFC/106 PBMC (CI: 66–
132), Figure 1e and 105 SFC/106 PBMC (CI: 51–215) in Kenya, 
Figure 1f. These responses did not differ significantly from those 
observed in malaria-naive volunteers in the United Kingdom at 
the same time point (Figure 1g).
Vaccination induces broad responses to the TRAP 
antigen
At every time point studied, responses to the TRAP antigen 
were focused toward the first three peptide pools representing 
the N-terminal region, corresponding to amino acids (aa) 1-300, 
and the last peptide pool (aa 501-557) covering the C-terminal 
end. Responses to the central region (aa 300-500) of the antigen 
were rarely detected. The hierarchy of immunodominance for 
responses to the peptide pools was similar between malaria-naive 
and malaria-exposed vaccinees at each time point (Figure 2a–
c). After each vaccination, the breadth of the immune response 
increased, as determined by the median number of peptide pools 
recognized, from 1 pool after ChAd63 vaccination in Kenyan par-
ticipants to 3 after MVA vaccination. In Gambian participants, the 
breadth of response increased from 2 pools after ChAd63 to 3 at 
1-week post-MVA and 4 pools at 5 weeks post-MVA.
Prime-boost immunization induces signiﬁcant 
increases in IgG responses in both African trials
Humoral immunity to TRAP before and after vaccination was 
assessed by IgG ELISA using a protein of the 3D7 strain of TRAP. 
Pre-existing anti-TRAP IgG responses were compared between 
malaria-naive and exposed volunteers. Titers in the UK volun-
teers were significantly lower than those in both Gambian and 
Kenyan vaccinees (P < 0.001, Kruskall-Wallis test with Dunn’s 
multiple comparison posttest, Figure 3a).
There was no significant difference in antibody titer to TRAP 
between groups receiving low- or high-dose ChAd63 ME-TRAP 
at any time point in either trial (P > 0.05, two-tailed Mann–
Whitney test, data not shown), and so, statistical analysis of 
increases was performed on combined data. Kinetics of antibody 
induction are shown in Figure 3b. Increases in antibody titers 
across both groups were significant after priming and boosting, 
(P < 0.001, Kruskall-Wallis test with Dunn’s multiple comparison 
posttest comparing responses at D14 (Gambians only), D63, and 
D90 to baseline responses at D0). Peak responses at day 63 were 
238 (CI: 159–358) ELISA units (EU) and 295 EU (CI: 235–370) 
in Gambian and Kenyan recipients respectively, and there was no 
significant difference in antibody response between sites (P = 0.3, 
two-tailed Mann–Whitney test).
Antibodies to the adenovirus vector do not inhibit 
responses to the vaccine antigen
Pre-existing immunity to ChAd63 was generally low in both tri-
als, with geometric mean titer of 192 (CI: 147–251) in Gambians 
and 214 (CI: 104–442) in Kenyans (Figure 3c). Fourteen days 
after immunization with ChAd63 ME-TRAP, titers increased 
significantly (The Gambia 1,157, CI: 710–1,890; Kenya 1,255, CI: 
696–2,264; P < 0.0001 using two-tailed t-test on log transformed 
data comparing pre- and postvaccination titers for each trial), and 
there was a strong positive correlation between anti-ChAd63 neu-
tralizing antibody titers pre- and postvaccination (Spearman’s r 
= 0.63, P < 0.0001, Figure 3d). There was a weak negative cor-
relation between pre-existing humoral immunity to ChAd63 and 
T-cell responses to the vaccine at day 14 (Spearman’s r = −0.3, P = 
0.03, Figure 3e), however this association disappeared after boost-
ing with MVA (Spearman’s r = −0.2, P = 0.3, Figure 3f), suggesting 
that boosting of pre-existing immunity to the vector by vaccina-
tion was not associated with inhibition of cellular immunity to 
the vaccine. There was a trend toward a weak positive relation-
ship between pre-existing cellular immunity to ME-TRAP and 
the response to ChAd63-ME-TRAP (Spearman’s r = 0.3, P = 0.07, 
Figure 3g). After boosting with MVA, a highly significant rela-
tionship between T-cell responses measured postprime and post-
boost was apparent (Spearman’s r = 0.6, P < 0.000 1, Figure 3h).
Dose of ChAd63 ME-TRAP and route of 
administration of MVA ME-TRAP do not affect 
immunogenicity
Cytokine secretion by CD4+ and CD8+ T cells was assessed by 
flow cytometry with intracellular cytokine staining using a single 
pool of peptides. Prior to vaccination, frequencies of cytokine-
secreting T cells were low, with approximately equal distribution 
of cytokine production between CD4+ and CD8+ T cells in both 
trials (Supplementary Figure S2a). In Kenyan vaccinees, cyto-
kine production was compared between volunteers vaccinated 
with MVA ME-TRAP via the intradermal (i.d.) and intramuscular 
(i.m.) routes. Prior to boosting with MVA, there were no signifi-
cant differences in cytokine production between groups after cor-
rection for multiple comparisons for vaccinees primed with either 
Figure 2 Percentage of vaccinees responding to each peptide pool. (a) prevaccination, (b) day 14 postprime with ChAd63 ME-TRAP, (c) 7 days 
postboost with MVA ME-TRAP. TRAP, thrombospondin-related adhesive protein.
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low (1 × 1010 vp, Supplementary Figure S2b) or high (5 × 1010 vp, 
Supplementary Figure S2c) doses of ChAd63 ME-TRAP. After 
boosting, at day 63 (7 days post-MVA), no significant differences 
were detected for different routes of MVA administration in either 
of the dose groups (Supplementary Figure S2d,e), confirming 
the findings previously reported of the same responses assessed 
by IFN-γ ELISPOT. Therefore, subsequent analyses are presented 
with data for different routes of MVA administration combined.
In both African trials, the effect of priming dose of ChAd63 
ME-TRAP on the magnitude of cytokine-secreting T-cell fre-
quencies was assessed by flow cytometry. Irrespective of the dose 
of the priming vector used, IFN-γ was predominantly secreted by 
CD8+ T cells (pie-charts, Figure 4a,b). Secretion of IFN-γ, IL-2, 
and TNF-α could be detected from both CD4+ and CD8+ T cells 
at day 14, although responses tended to be higher in Kenyans. 
Seven days after boosting with MVA, IFN-γ secretion was more 
equally distributed between CD4+ and CD8+ T cells, particularly 
among vaccinees that received the higher dose of ChAd63 (pie-
charts, Figure 4c,d).
No significant differences in magnitude of cytokine secreting 
T-cell populations were observed for different doses of ChAd63 
within either trial; therefore, statistical analyses use data com-
bined for both priming doses. At each trial site, frequencies 
of cytokine-secreting cells increased after each vaccination 
(Table 2 and scatter plots, Figure 4c,d). Within individual trial 
sites, increases were not statistically significant, however when 
data across trials were combined, increases in the magnitude of 
CD4+ IFN-γ+ and CD4+ TNFα+ populations reached signifi-
cance (P = 0.007 and P = 0.009, Kruskall-Wallis test with Dunn’s 
multiple comparison) and the increase in CD4+ IL2-secreting 
Figure 3 Antibody responses and effect of pre-existing immunity on responses to vaccination. (a) Prevaccination anti-thrombospondin-
related adhesive protein (TRAP) IgG responses, P < 0.001 for UK versus Kenya, P < 0.01 for UK versus The Gambia analyzed using Kruskal-Wallis 
with Dunn’s multiple comparison test. Line represents geometric mean. (b) Geometric means of log endpoint titers for IgG ELISA against 
3D7 TRAP stratiﬁed by dose of ChAd63. Dashed line represents 1 × 1010 viral particles (vp) and solid line 5 × 1010 vp ChAd63 ME-TRAP, P < 
0.001, Kruskall-Wallis test with Dunn’s multiple comparison posttest comparing responses at D14, D63, and D90 to baseline responses at D0. 
(c) Neutralizing antibody titers to the ChAd63 vector pre- and postimmunization at 14 days for African trials, ****P < 0.0001, paired two-tailed 
t-test. (d) Correlation between pre- and postimmunization neutralizing antibody titers. (e) Lack of association between cellular immune response 
to TRAP and antibody response to the ChAd63 vector at 14 days postimmunization. (f) Postprime and postboost immunization neutralizing 
antibody titers. (g) Correlation between pre-existing immunity to the ME-TRAP vaccine and responses at 14 days postvaccination with ChAd63. 
(h) Relationship between magnitude of response to priming vaccination at day 14 post-ChAd63 and boosting vaccination at day 63 (7 days post-
MVA). Spearman’s two-tailed correlation coefﬁcients shown with P value. Upwards pointing triangles represent vaccinees primed with 1 × 1010 vp 
ChAd63 ME-TRAP in Kenya, downward pointing triangles 5 × 1010 vp in Kenya, circles 1 × 1010 vp ChAd63 ME-TRAP in The Gambia, and squares 
5 × 1010 vp ChAd63 ME-TRAP in The Gambia.
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cells showed a trend toward an increase after vaccination (P = 
0.07). Increases in CD8+ cytokine-secreting T-cell populations 
were not significant as frequencies of these populations were 
low. Analysis of polyfunctionality showed that a mixture of cell 
phenotypes was induced in all volunteers with single-, double-, 
and triple-cytokine secreting cells detected in both the CD4+ 
and CD8+ population (Figure 5a,b). CD8+ T cells secreting 
IFN-γ, but not IL-2 or TNF-α (mono-functional), which have 
been previously shown to associate with protection against 
CHMI with this vaccine regimen were detected from vaccinees 
Figure 4 Responses to prime-boost immunization with ChAd63 and MVA ME-TRAP by ICS. Pie charts show proportion of IFN-γ secreted from 
CD4+ (light grey) and CD8+ (dark grey) as a proportion of total IFN-γ production. Scatter plots show individual responses to thrombospondin-related 
adhesive protein (TRAP) peptides from peripheral blood mononuclear cells stratiﬁed by trial and dose of priming immunization. Bars denote geo-
metric mean. Cytokine frequencies from CD4+ (a) and CD8+ (b) T cells 14 days after priming immunization with ChAd63 ME-TRAP. c and d display 
cytokine secretion from CD4+ (c) and CD8+ (d) T cells after boosting with MVA ME-TRAP. Frequencies were compared with the Kruskall-Wallis test 
with Dunn’s multiple comparison posttest, *P < 0.05, **P < 0.01. Upwards pointing triangles represent vaccinees primed with 1 × 1010 viral particles 
(vp) ChAd63 ME-TRAP in Kenya, downward pointing triangles 5 × 1010 vp in Kenya, circles 1 × 1010 vp ChAd63 ME-TRAP in The Gambia, and squares 
5 × 1010 vp ChAd63 ME-TRAP in The Gambia. ICS, ﬂow cytometry with intracellular cytokine staining; LLD, lower limit of detection of the assay.
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in both trials, however the frequency in volunteers from the 
trial in Kenya was significantly higher than that in The Gambia 
or the United Kingdom (P = 0.008, Kruskall-Wallis with Dunn’s 
multiple comparison correction, Figure 6).
DISCUSSION
Prime-boost vaccination with ChAd63 and MVA ME-TRAP 
has demonstrated excellent immunogenicity in these two phase 
1b trials in healthy adults in regions of low-to-moderate malaria 
transmission. Despite presumably repeated exposure to malaria, 
pre-existing baseline T-cell responses to the TRAP antigen mea-
sured by ex vivo ELISPOT did not differ between malaria-naive 
and exposed volunteers, suggesting that TRAP is not a major 
target for naturally acquired cellular immunity. Similarly, after 
priming and boosting immunizations, T-cell responses to the vac-
cine antigen were of the same magnitude as those in UK malaria-
naive vaccinees, suggesting that vaccination does not boost T-cell 
responses primed by natural exposure, despite the evidence of 
central memory responses to TRAP in Kenyan adults.19
The T9/96 and 3D7 strains of P. falciparum represent the 
breadth of genetic diversity of the TRAP antigen with 6.1% amino 
acid variation.26 Despite this, responses to the heterologous 3D7 
strain (used for CHMI studies) were of a similar order of mag-
nitude in both cohorts suggesting that this vaccine will not be 
affected substantially by antigenic polymorphism, as T cells 
induced by vaccination with the T9/96 strain were highly cross-
reactive. Responses were detected to pools representing 46 of the 
56 peptides spanning the TRAP protein (82%), demonstrating the 
high number of potential epitopes within this antigen. The breadth 
of the immune response induced by vaccination was also large and 
indicated that a number of epitopes over the length of the anti-
gen were recognized. Given the potential diversity of HLA types 
in populations that might be targeted with a malaria vaccine, the 
finding of potentially highly promiscuous epitopes is encouraging.
More than a decade ago, the approach of combining a 
DNA priming vaccination with MVA boosting using the same 
ME-TRAP construct induced very modest T-cell responses by 
ex vivo ELISPOT (GM 69.8 SFC/106 PBMC) that failed to reduce 
the rate of malaria infection in Gambian men,27,28 most likely as 
a result of insufficient immunogenicity. Previous trials of prime-
boost viral vectored vaccines with this antigen that employed two 
pox viruses (albeit different viruses) as both priming and boost-
ing vectors failed to elicit sufficiently potent immunity to medi-
ate protection in volunteers in coastal Kenya or The Gambia.18–20 
Although the immunogenicity induced by the fowlpox-MVA 
ME-TRAP vaccination regime was more immunogenic than 
DNA-MVA, the peak response was still modest at 185 SFC/106 
PBMC. After a double prime with fowlpox ME-TRAP, peak 
responses reached 389 SFC/106 PBMC, however this was also 
insufficient to induce protection against febrile malaria among 
young children in Kenya. In adults, immunogenicity in both set-
tings was lower than in malaria-naive adults, most likely due to 
immunosuppression caused by malaria. Data from Kenyan chil-
dren showed reduced T-cell responses after both vaccination with 
poxviruses, and natural exposure was associated with parasitae-
mia and clinical malaria.29
Here, we show that replacement of the fowlpox or DNA prim-
ing vectors with the chimpanzee adenovirus vector has both 
increased the magnitude of the peak response fourfold to 1254 
SFC per million PBMC and resulted in increased induction of 
CD8+ T-cell-mediated immunity—a prerequisite for an effective 
pre-erythrocytic vaccine.30 This suggests that adenoviral vectors 
may be more robust to the immunosuppressive effects of malaria 
than poxvirus vectors, a potentially useful characteristic for vac-
cines against other diseases in malaria-endemic regions. In addi-
tion, responses were maintained above baseline in the Kenyan 
vaccinees for 8 months, demonstrating useful durability of effec-
tor memory type cellular immunity and potentially greater lon-
gitudinal central memory. Vaccination with ChAd63 and MVA 
ME-TRAP also induced modest, but significant increases in 
TRAP IgG levels, despite a higher level of pre-existing humoral 
immunity than in malaria-naive vaccinees, suggesting that prior 
immunity to TRAP does not inhibit development of vaccine-
induced antibodies.
Table 2 Geometric mean frequencies of cytokine-secreting T cells by 
trial site and time point
T-cell population/ 
time point
Gambian 
vaccinees: 
geomean  
(95% CI)
Kenyan 
vaccinees: 
geomean  
(95% CI)
P value 
(sites 
combined)
CD4+ T cells
IFN-γ+
d0 (pre-vacc) 0.005 (0.002–0.01) 0.02 (0.005–0.07) 0.007
d14 (post-ChAd63) 0.008 (0.003–0.02) 0.04 (0.01–0.1)
d63 (7 days post-MVA) 0.02 (0.008–0.07) 0.1 (0.03–0.3)
IL-2+
d0 (pre-vacc) 0.03 (0.009–0.09) 0.05 (0.01–0.2) 0.07
d14 (post-ChAd63) 0.01 (0.003–0.04) 0.1 (0.04–0.2)
d63 (7 days post-MVA) 0.04 (0.007–0.2) 0.2 (0.07–0.7)
TNFα+
d0 (pre-vacc) 0.009 (0.003–0.03) 0.04 (0.01–0.2) 0.009
d14 (post-ChAd63) 0.007 (0.002–0.02) 0.01 (0.005–0.04)
d63 (7 days post-MVA) 0.01 (0.005–0.04) 0.08 (0.03–0.2)
CD8+ T cells
IFN-γ+
d0 (pre-vacc) 0.006 (0.002–0.02) 0.03 (0.008–0.1) ns
d14 (post-ChAd63) 0.01 (0.003–0.03) 0.06 (0.02–0.2)
d63 (7 days post-MVA) 0.01 (0.004–0.04) 0.04 (0.009–0.2)
IL-2+
d0 (pre-vacc) 0.009 (0.003–0.02) 0.07 (0.02–0.3) ns
d14 (post-ChAd63) 0.005 (0.002–0.01) 0.1 (0.05–0.3)
d63 (7 days post-MVA) 0.01 (0.004–0.04) 0.2 (0.04–0.5)
TNF-α+
d0 (pre-vacc) 0.01 (0.003–0.03) 0.1 (0.03–0.4) ns
d14 (post-ChAd63) 0.006 (0.002–0.02) 0.03 (0.008–0.08)
d63 (7 days post-MVA) 0.004 (0.003–0.007) 0.1 (0.03–0.3)
P values are for Kruskall Wallis test with Dunn’s multiple comparison posttest 
comparing responses postvaccination to those at time point 0.
CI, conﬁdence interval; IFN, interferon; IL, interleukin; MVA, modiﬁed vaccinia 
Ankara; ns, not statistically signiﬁcant; TNF, tumor necrosis factor.
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Contrary to prevailing theory, pre-existing immunity to this 
adenoviral vector did not inhibit the subsequent immunogenic-
ity of the vaccine, in fact a trend toward a weak positive asso-
ciation was detected. Our group has previously demonstrated a 
much stronger positive association in UK volunteers, however the 
finding reported here in regions of increased prevalence of neu-
tralizing antibodies to the adenoviral vector is pertinent for the 
potential deployment of this vaccine in an endemic population 
and similar levels of seroprevalence to this vector have recently 
been reported in Burkina Faso.31 Given the strong correlation 
Figure 5 Polyfunctionality of peak T-cell responses at day 63. Analysis of cytokine secretion from CD4+ and CD8+ T cells was performed using a 
Boolean gating strategy in SPICE. Pie charts represent the proportion of the immune response represented by each combination of cytokines shown in 
the bar chart. Bar charts show the frequency of each population with bars representing median responses. (a) CD4+ responses. (b) CD8+ responses. 
SPICE, simpliﬁed presentation of incredibly complex evaluations.
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between responses after priming and boosting, the magnitude 
of the peak response is clearly related to the magnitude of the 
response to ChAd63 ME-TRAP, rather than any humoral response 
to the adenoviral vector.
The dose of ChAd63 used for priming did not significantly 
affect the immunogenicity of the vaccine by any of the measures 
we studied, in agreement with the first UK phase 1 dose-escala-
tion study of the ChAd63 ME-TRAP priming immunization.21 
Furthermore, administration of the boosting MVA ME-TRAP 
vector by either the i.m. or i.d. routes had no effect on responses 
to the TRAP insert. Given that i.m. immunization is easier to per-
form with reduced local reactogenicity,25 future trials of the MVA 
ME-TRAP vaccine will employ this route of administration.
Phenotyping of vaccine-induced T-cell subtypes by flow 
cytometry with intracellular cytokine staining revealed produc-
tion of IFN-γ, IL-2, and TNF-α from CD4+ and CD8+ T cells in 
all combinations. In a previously reported study of the efficacy of 
ChAd63 and MVA ME-TRAP in the United Kingdom, we showed 
21% sterile efficacy increasing to more than 50% efficacy when 
including delay to detectable parasitaemia.24 We then demon-
strated a correlation between efficacy and frequency of monofunc-
tional CD8+ T cells secreting IFN-γ, a finding also observed in a 
nonhuman primate model of sporozoite-induced protection.32 In 
this study, the frequency of this protective CD8+ T-cell popula-
tion was significantly higher in Kenyan vaccinees than in the UK 
study, suggesting that this vaccine may be more protective in this 
population, particularly given that the infectious inoculum during 
natural exposure may well be lower than in the CHMI model of 
sporozoite challenge.33
Although practical limitations prevented flow cytometric 
analysis of the memory phenotype of the vaccine-induced T-cell 
response, previous studies in mice using the same vaccine regi-
men clearly identified CD8+ T effector memory T cells as essential 
for protection against the pre-erythrocytic stage of malaria.12 In 
humans, the exact nature of T-cell phenotype best suited to medi-
ating durable protective immunity is not clear, with different mod-
els proposing both effector and central memory T cell as more 
important.34,35 Future studies of vaccine efficacy could address 
these conflicting positions, although markers for discrimination 
of effector and memory populations in human T cells are complex 
due to the heterogeneous nature of the phenotypes.36
The initial report of these two phase 1 clinical trials demon-
strated excellent safety with very acceptable reactogenicity profiles 
for both ChAd63 and MVA ME-TRAP.25 In this report, we have 
detailed the very potent cellular immunogenicity of this vaccine 
for two increasing doses of the ChAd63 priming vector and two 
routes of administration for the MVA vector. This regimen elic-
its a broad CD4+ and CD8+ T-cell-mediated immune response 
including a phenotype shown to induce protective efficacy against 
sporozoite challenge. The combination of an acceptable safety 
profile and impressive immunogenicity provides a clear rationale 
for phase 1 age de-escalation studies in children in semi-immune 
populations and phase 2b efficacy studies in adults in endemic 
regions. Studies of both such designs are underway. The data pre-
sented here also highlight the potential utility of these viral vec-
tors as vaccines for other diseases where induction of high levels 
of T-cell immunity is helpful or necessary for protection.
MATERIALS AND METHODS
The objectives, setting, participant demographics, clinical study design, 
and methods for vaccine production used in these clinical trials have been 
described in detail elsewhere.25 Brief details are repeated here.
Study settings and design. The first trial was conducted at the Medical 
Research Council field site located within Sukuta Health Centre in Kombo 
North district of The Gambia, West Africa. Sukuta village has an estimated 
population of 17,000 (2003 census). The climate is typical of sub-Saharan 
Africa with a long dry season lasting from December to June followed by a 
relatively short rainy season from July to November when the majority of 
P. falciparum malaria transmission occurs.37
The second trial was conducted in Vipingo, Kilifi County, Kenya, East 
Africa. Participants were recruited from the Rea Vipingo Sisal Plantation 
Estates in Kilifi, which has over 1,000 employees and a land area of 
3,950 hectares. In Kilifi, there are two seasons of high transmission of 
P. falciparum malaria coinciding with the long monsoon rains (April to 
June) and the short rains (October to December).38
The third trial was conducted in Oxford, UK, and local malaria-naive 
volunteers were recruited.
We conducted two phase 1b open-label malaria vaccine trials. Both 
trials evaluated low- (1 × 1010 vp) and high-dose (5 × 1010 vp) ChAd63 ME-
TRAP. The trial in Kenya also compared i.m. and i.d. routes of administration 
of 2 × 108 p.f.u. MVA ME-TRAP. In The Gambia, eligible participants were 
allocated to receive either ChAd63 ME-TRAP 1 × 1010 vp (group 1; n = 6) 
or ChAd63 ME-TRAP 5 × 1010 vp (group 2; n = 10) administered i.m. in 
the deltoid. All participants were subsequently vaccinated in the opposite 
arm 56 days later with 2 × 108 plaque forming units (p.f.u.) MVA ME-TRAP 
administered i.m.. In the Kenyan trial, eligible participants were allocated 
to receive either ChAd63 ME-TRAP 5 × 109 vp (group 1; n = 10) or ChAd63 
ME-TRAP 5 × 1010 vp (group 2; n = 20) administered i.m. in the deltoid. 
All participants were subsequently vaccinated in the opposite arm 56 
days later with 2 × 108 p.f.u. MVA ME-TRAP. Participants in each group 
were randomized 1:1 to receive MVA ME-TRAP administered i.m. or i.d. 
Blood samples for immunology were collected on day 0 (day of ChAd63 
ME-TRAP vaccination), day 14, day 28, day 56 (day of MVA ME-TRAP 
vaccination), day 63, day 90, and day 300 (The Gambia) or day 308 (Kenya).
The UK trial was a phase 2a sporozoite challenge study (CHMI) with 
volunteers receiving ChAd63 ME-TRAP 5 × 1010 vp administered i.m. 
followed by of 2 × 108 p.f.u. MVA ME-TRAP administered i.d. 56 days 
later.24 Data shown here are from blood samples collected for immunology 
on day 0, 14, 28, 56, and 63; no data are shown post-CHMI. Some data 
were reanalyzed for comparability with methods employed in this study. 
Figure 6 Frequency of monofunctional CD8+ T cells (CD8+ T cells 
secreting IFN-γ, but not IL-2 or TNF-α) was signiﬁcantly higher in 
Kenyan than Gambian or UK vaccinees. Frequencies were compared 
with the Kruskall-Wallis test with Dunn’s multiple comparison posttest, 
*P < 0.05. Line shows geometric mean.
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In particular, the IgG antibody data shown here were performed using 
a standardized anti-TRAP ELISA rather than the end-point titer assay 
described in the previous publication, however agreement between the 
two methods was excellent and data correlated extremely well (Spearman’s 
r = 0.9, two-tailed P < 0.0001).
Ethical and regulatory approval. The clinical trial protocols and associ-
ated documents were approved by Gambia Government/Medical Research 
Council Joint Ethics Committee and The Kenya Medical Research Institute 
National Ethics Committee, respectively. Documents for all clinical tri-
als were reviewed and approved by the Oxford Tropical Research Ethics 
Committee. Regulatory approval was given by the Medicines Board of The 
Gambia, The Pharmacy and Poisons Board of Kenya, and the Medicines 
and Healthcare products Regulatory Agency, respectively. All partici-
pants gave documented informed consent prior to any study procedure 
being undertaken. The study was conducted according to the principles 
of the Declaration of Helsinki (2008) and the International Conference on 
Harmonization Good Clinical Practice guidelines. An independent Data 
and Safety Monitoring Board and local safety monitors provided safety 
oversight and Good Clinical Practice compliance was independently mon-
itored by an external organization at both trial sites (Appledown Clinical 
Research, Great Missenden, UK). Trials were registered with Pan African 
Clinical Trial Registry (Ref: PACT ATMR 2010020001771828 & PACTR 
201008000221638); http://www.pactr.org/ and ClinicalTrials.gov (Ref: 
NCT01373879, NCT01379430 & NCT00890760); http://clinicaltrials.gov/
ct2/home.
Standardization of immunological methods. Staff from the Kenyan and 
Gambian immunology laboratories visited The Jenner Institute for train-
ing on immunology protocols that were standardized across all three sites. 
Staff from the Jenner Institute visited both African institutes to help with 
sample processing and equipment optimization. For cellular immunology, 
reagents were provided from The Jenner Institute after batch testing and 
the same batch of peptides were used in all studies. ELISAs and neutral-
izing antibody assays on samples from The Gambia and UK studies were 
performed at the Jenner Institute and at KEMRI for the Kenyan study 
using reagents supplied by the Jenner Institute. Data analysis was largely 
performed independently at each site with quality control performed by a 
single senior scientist at the Jenner Institute. All assays of cellular immu-
nity reported here were performed on freshly isolated PBMC.
Ex vivo ELISPOT assays. Ex vivo (18-hour stimulation) ELISPOT assays 
were performed using Multiscreen IP ELISPOT plates (Merck Millipore, 
Billerica, MA), human IFN-γ SA-ALP antibody kits (Mabtech, Stockholm, 
Sweden), and BCIP NBT-plus chromogenic substrate (Moss, Pasadena, 
MD). Cells were cultured in RPMI (Sigma, Poole, UK) containing 10% 
heat-inactivated, sterile-filtered fetal calf serum, previously screened for 
low reactivity (Labtech International, Uckfield, UK). Antigens were tested 
in duplicate with 250,000 freshly isolated PBMC added to each well of the 
ELISPOT plate.16 TRAP peptides were 20 amino acids in length, overlap-
ping by 10 amino acids (Neopeptide, Cambridge, MA), assayed in 6 pools 
of 7–10 peptides at 10 μg/ml. Responses were averaged across duplicates, 
responses in unstimulated (negative control) wells were subtracted, and 
then responses in individual pools were summed for each strain of the 
TRAP antigen. ME responses were assayed in a single pool and peptide 
pool configurations are shown in Supplementary Tables S1 and S2. 
Staphylococcal enzyme B (SEB, 0.02μg/ml) and phytohemmagglutinin-
L (10 μg/ml, Sigma) were used as a positive control. Plates were counted 
using an AID automated ELISPOT counter (AID Diagnostika GmbH, 
Strassberg, Germany; algorithm C), using identical settings for all plates, 
and counts were adjusted only to remove artifacts. Responses to the nega-
tive control were always less than 90 SFC per million PBMC and the 
median across both trials was 11 SFC per million PBMC. Pools were con-
sidered positive if the response was greater than 11 SFC per million PBMC 
and four times higher than the negative control for that assay. The lower 
limit of detection for the assay is 24 SFC per million PBMC for peptide 
pools and 4 SFC for individual pools.
Flow cytometry. PBMC were separated by density centrifugation from 
heparinized whole blood and resuspended in polypropylene tubes at 
1 × 106 PBMC per ml in RPMI containing 10% heat-inactivated, batch-
tested, sterile-filtered fetal bovine serum, 1% L-glutamine, 1% penicil-
lin/streptomycin, and 1 μg/ml each of anti-CD28 and anti-CD49d (BD 
Biosciences, Oxford, UK). Samples were stored at room temperature 
prior to processing, which was completed within 6 hours of venipuncture. 
Cell counts were performed using trypan blue staining and a microscope 
according to an established SOP in the laboratory. Cells were then stimu-
lated overnight at 37 °C with 5% CO2, either with a pool of 56 peptides at 
2 μg/ml spanning the entire length of the TRAP protein from the T9/96 
strain of P. falciparum comprising 20mers overlapping by 10 amino acids, 
SEB or an unstimulated control containing an equivalent concentration of 
DMSO to the TRAP peptide pool (0.3%). Brefeldin A (BD Biosciences) 
was after 2 hours into the incubation at 1 μg/ml. Cells were then washed in 
fluorescence-activated cell sorting buffer (phosphate-buffered saline (PBS) 
containing 1% bovine serum albumin (BSA) and 0.01% sodium azide, 
Sigma) and stained for viability with LIVE/DEAD aqua amine reactive dye 
(Life technologies, Carlsbad, CA) for 20 minutes at 4 °C in the dark, after 
which a cocktail of antibodies for surface marker staining was added and 
incubated for 30 minutes at 4 °C in the dark. Cells were washed again in 
fluorescence-activated cell sorting buffer, then permeabilized for 30 min-
utes with Cytofix/Cytoperm (BD Biosciences), and washed in permeabi-
lization buffer (BD Biosciences). A cocktail of antibodies for intracellular 
staining was then added and incubated for 30 minutes at room tempera-
ture in the dark. Antibody cocktails are described in Supplementary 
Table S3. Cells were washed in permeabilization buffer and resuspended 
in PBS containing 1% paraformaldehyde, prior to acquisition on CyAn 
flow cytometers (Beckman Coulter, High Wycombe, UK) on the day of 
staining. Compensation control beads (Compbeads, BD Biosciences) were 
stained according to the manufacturers instructions using the same con-
centration of antibody used for cells to for compensation between param-
eters, and unstained cells were used to adjust forward and side scatter 
photo-multiplier tube voltages.
Analysis of ﬂow cytometry data. At least 50,000 live CD3+ cells were ana-
lyzed per sample. Data were prepared and analyzed using FlowJo v8.8.6 
(Treestar, Ashland, Oregon), Pestle v1.6 and Spice v5.05 (Mario Roederer, 
Vaccine Research Centre, NIAID, NIH). A hierarchical gating strategy was 
used as described in Supplementary Figure S1. Responses to peptide were 
determined after subtraction of the response in the unstimulated control 
for each sample. Pie charts were created using absolute measures with a 
threshold of 0.002%. For analyses of multiple cytokine function, all sam-
ples had >10,000 CD4+ or CD8+ T cells in the parent population. Samples 
where a response to the positive control of greater than 1% cytokine posi-
tive CD4+ or CD8+ T cells could not be detected were excluded from the 
analysis. The lower limit of detection for the assay was 0.002%, and a posi-
tive response was greater than two times the medium control for the cor-
responding sample.
Antivector neutralizing antibody assay. One day prior to performing the 
assay, GripTite 293 cells (Life Technologies) were seeded in 96-well plates 
(3 × 104 cells/well). Heat-inactivated test samples were diluted fourfold from 
1:9 to 1:2,304 in 10% sterile-filtered fetal bovine serum in Dulbecco's modi-
fied Eagle's medium and incubated 1:1 with ChAd63 expressing the secreted 
alkaline phosphatase gene (8 × 107 vp/ml) for 1 hour at 37 °C. Serum and 
virus were then added to 293 cells in a volume of 200 μl in duplicate for 1 hour, 
after which sample and virus were aspirated and replaced with fresh 10% 
fetal bovine serum Dulbecco's modified Eagle's medium. A virus-only con-
trol was included. After 22–26 hours at 37 °C, 50 μl of medium was assayed 
for SEAP activity using a Phospha-Light TROPIX phosphatase assay (Life 
Technologies) in black assay plates, and luminescence was measured after 
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45 minutes on a Varioskan Flash Luminometer (ThermoFisher, Waltham, 
MA). Antivector neutralization titers were defined as the dilution of serum 
showing 50% reduction in SEAP activity, based on observed % inhibition 
values relative to SEAP activity from virus alone. Antivector antibodies were 
measured in serum in The Gambia and plasma for Kenyans, according to 
sample availability and local clinical practice, however we have determined 
that these sample types are equivalent for this assay.
Serum IgG antibody responses. Antibody responses were measured 
by anti-TRAP IgG sandwich ELISA. Nunc-Immuno 96 well plates were 
coated with 0.5 μg/ml of TRAP antigen in carbonate-bicarbonate coating 
buffer and left overnight at 4 °C. Plates were washed 6× with PBS-Tween 
(PBS/T), then blocked with 1% BSA in PBS/T for 1 hour at room tem-
perature. Serum or plasma was diluted in PBS/T containing 0.2% BSA at 
concentrations of 1:100, 1:500, or 1:1,000, and added in triplicate. Samples 
from days 0 (ChAd63 vaccination), 28, 56 (MVA vaccination), 63, and 300 
were analyzed. Plates were incubated at room temperature for 2 hours; 
then washed as before. A secondary antibody (goat anti-human whole 
IgG conjugated to alkaline phosphatase, Sigma) was added at a dilution of 
1:1,000 in PBS/T 0.2% BSA for 1 hour at room temperature. After a final 
wash, plates were developed by adding 4-nitrophenyl phosphate in dietha-
nolamine buffer (Pierce, Loughborough, UK).
A positive reference standard (made from pooled TRAP-positive serum) 
was used on each plate to give a standard curve. It was added in duplicate 
at an initial dilution of 1:100 (in PBS/T 0.2% BSA) and diluted twofold 10 
times, starting with an arbitrary value of 20 antibody units. Four blank wells 
(zero antibody units) were also designated. The optical density values were 
then fitted to a 4 parameter standard curve using SOFTmax PRO software.15 
An internal control was included on every plate in triplicate made up from a 
1:800 dilution (in PBS/T 0.2% BSA) of the positive standard. Optical density 
was read at 405 nm using an ELx800 microplate reader (Cole Parmer, 
London, UK). Test sera antibody units were calculated from their optical 
density values using the parameters estimated from the standard curve.
Statistical analysis. Group data are geometric means unless otherwise 
stated with 95% CI. The matched pairs analysis excludes volunteers with 
missing data at any time point. A Kruskall-Wallis test was used to com-
pare increases in T-cell frequencies in time courses with Dunn’s multiple 
comparisons posttest used to compare response pre- and postvaccination. 
For statistical analyses, an α-level of 0.05 was considered significant and all 
P values are two-tailed. All analyses were performed in GraphPad Prism, 
Mac version 5 (GraphPad, La Jolla, CA).
SUPPLEMENTARY MATERIAL
Figure S1. Sample gating strategy for ﬂow cytometry analysis.
Figure S2. Effect of route of MVA administration on responses to 
TRAP peptides by ICS, expressed as the percentage of cytokine-secret-
ing CD4+ or CD8+ T cells.
Table S1. TRAP peptide pool format.
Table S2. ME peptide pool format.
Table S3. Reagents used for ﬂow cytometry staining.
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